Role of platelet activating factor in endotoxemic acute renal failure in the male rat

J. P. Tolins, G. M. Vercellotti, M. Wilkowske, B. Ha, H. S. Jacob, Leopoldo Raij

Research output: Contribution to journalArticle

Abstract

We have developed a model of endotoxemic acute renal failure in the anesthetized male rat in which acute endotoxin infusion induces renal vasoconstriction and decreased glomerular filtration rate (GFR) in the absence of systemic hypotension. Because increased levels of platelet activating factor (PAF) have been observed in experimental models of endotoxemia, we pretreated rats with PAF receptor antagonist BN 52021 or SRI 63-675 before administering endotoxin. Compared with treatment with vehicle, treatment with BN 52021 led to significant preservation of RBF, GFR, and urine flow rate. Pretreatment with SRI 63-675 resulted in significant improvement in RBF while completely preventing the fall in GFR and urine flow rate. Intrarenal artery infusion of exogenous PAF (30 ng/kg/min) resulted in renal vasoconstriction, decreased GFR, and oliguria. These effects were also prevented by pretreatment with SRI 63-675. Thus, the adverse renal hemodynamic effects of endotoxemia were blunted or prevented by pretreatment with PAF receptor antagonists. We conclude that endogenously produced PAF is an important mediator of endotoxemic acute renal failure.

Original languageEnglish
Pages (from-to)309-315
Number of pages7
JournalThe Journal of laboratory and clinical medicine
Volume113
Issue number3
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

ginkgolide B
Platelet Activating Factor
Glomerular Filtration Rate
Acute Kidney Injury
Rats
Endotoxemia
Vasoconstriction
Kidney
Endotoxins
Flow rate
Urine
Oliguria
Hemodynamics
Hypotension
Theoretical Models
Arteries
SRI 63-675
platelet activating factor receptor

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Tolins, J. P., Vercellotti, G. M., Wilkowske, M., Ha, B., Jacob, H. S., & Raij, L. (1989). Role of platelet activating factor in endotoxemic acute renal failure in the male rat. The Journal of laboratory and clinical medicine, 113(3), 309-315.

Role of platelet activating factor in endotoxemic acute renal failure in the male rat. / Tolins, J. P.; Vercellotti, G. M.; Wilkowske, M.; Ha, B.; Jacob, H. S.; Raij, Leopoldo.

In: The Journal of laboratory and clinical medicine, Vol. 113, No. 3, 01.01.1989, p. 309-315.

Research output: Contribution to journalArticle

Tolins, JP, Vercellotti, GM, Wilkowske, M, Ha, B, Jacob, HS & Raij, L 1989, 'Role of platelet activating factor in endotoxemic acute renal failure in the male rat', The Journal of laboratory and clinical medicine, vol. 113, no. 3, pp. 309-315.
Tolins JP, Vercellotti GM, Wilkowske M, Ha B, Jacob HS, Raij L. Role of platelet activating factor in endotoxemic acute renal failure in the male rat. The Journal of laboratory and clinical medicine. 1989 Jan 1;113(3):309-315.
Tolins, J. P. ; Vercellotti, G. M. ; Wilkowske, M. ; Ha, B. ; Jacob, H. S. ; Raij, Leopoldo. / Role of platelet activating factor in endotoxemic acute renal failure in the male rat. In: The Journal of laboratory and clinical medicine. 1989 ; Vol. 113, No. 3. pp. 309-315.
@article{0450cf6be47c46548f3e65766bbbe731,
title = "Role of platelet activating factor in endotoxemic acute renal failure in the male rat",
abstract = "We have developed a model of endotoxemic acute renal failure in the anesthetized male rat in which acute endotoxin infusion induces renal vasoconstriction and decreased glomerular filtration rate (GFR) in the absence of systemic hypotension. Because increased levels of platelet activating factor (PAF) have been observed in experimental models of endotoxemia, we pretreated rats with PAF receptor antagonist BN 52021 or SRI 63-675 before administering endotoxin. Compared with treatment with vehicle, treatment with BN 52021 led to significant preservation of RBF, GFR, and urine flow rate. Pretreatment with SRI 63-675 resulted in significant improvement in RBF while completely preventing the fall in GFR and urine flow rate. Intrarenal artery infusion of exogenous PAF (30 ng/kg/min) resulted in renal vasoconstriction, decreased GFR, and oliguria. These effects were also prevented by pretreatment with SRI 63-675. Thus, the adverse renal hemodynamic effects of endotoxemia were blunted or prevented by pretreatment with PAF receptor antagonists. We conclude that endogenously produced PAF is an important mediator of endotoxemic acute renal failure.",
author = "Tolins, {J. P.} and Vercellotti, {G. M.} and M. Wilkowske and B. Ha and Jacob, {H. S.} and Leopoldo Raij",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "113",
pages = "309--315",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Role of platelet activating factor in endotoxemic acute renal failure in the male rat

AU - Tolins, J. P.

AU - Vercellotti, G. M.

AU - Wilkowske, M.

AU - Ha, B.

AU - Jacob, H. S.

AU - Raij, Leopoldo

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We have developed a model of endotoxemic acute renal failure in the anesthetized male rat in which acute endotoxin infusion induces renal vasoconstriction and decreased glomerular filtration rate (GFR) in the absence of systemic hypotension. Because increased levels of platelet activating factor (PAF) have been observed in experimental models of endotoxemia, we pretreated rats with PAF receptor antagonist BN 52021 or SRI 63-675 before administering endotoxin. Compared with treatment with vehicle, treatment with BN 52021 led to significant preservation of RBF, GFR, and urine flow rate. Pretreatment with SRI 63-675 resulted in significant improvement in RBF while completely preventing the fall in GFR and urine flow rate. Intrarenal artery infusion of exogenous PAF (30 ng/kg/min) resulted in renal vasoconstriction, decreased GFR, and oliguria. These effects were also prevented by pretreatment with SRI 63-675. Thus, the adverse renal hemodynamic effects of endotoxemia were blunted or prevented by pretreatment with PAF receptor antagonists. We conclude that endogenously produced PAF is an important mediator of endotoxemic acute renal failure.

AB - We have developed a model of endotoxemic acute renal failure in the anesthetized male rat in which acute endotoxin infusion induces renal vasoconstriction and decreased glomerular filtration rate (GFR) in the absence of systemic hypotension. Because increased levels of platelet activating factor (PAF) have been observed in experimental models of endotoxemia, we pretreated rats with PAF receptor antagonist BN 52021 or SRI 63-675 before administering endotoxin. Compared with treatment with vehicle, treatment with BN 52021 led to significant preservation of RBF, GFR, and urine flow rate. Pretreatment with SRI 63-675 resulted in significant improvement in RBF while completely preventing the fall in GFR and urine flow rate. Intrarenal artery infusion of exogenous PAF (30 ng/kg/min) resulted in renal vasoconstriction, decreased GFR, and oliguria. These effects were also prevented by pretreatment with SRI 63-675. Thus, the adverse renal hemodynamic effects of endotoxemia were blunted or prevented by pretreatment with PAF receptor antagonists. We conclude that endogenously produced PAF is an important mediator of endotoxemic acute renal failure.

UR - http://www.scopus.com/inward/record.url?scp=45149144174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45149144174&partnerID=8YFLogxK

M3 - Article

VL - 113

SP - 309

EP - 315

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 3

ER -